Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices

International Journal of Technology Assessment in Health Care

Volumn 30, Issue 3, 2014, Pages 241-249

  Husereau, Don ^a,b,c   Henshall, Chris ^d,e   Jivraj, Jamil ^f  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^d BRUNEL UNIVERSITY   (United Kingdom)

^e HTAi Policy Forum   (Canada)

^f Health Technology Assessment International   (Canada)

Author keywords

Adaptive approaches; coverage; Drug Approval legislation and jurisprudence; Drug approval methods; Insurance; Licensure legislation jurisprudence

Indexed keywords

DECISION MAKING; INSURANCE;

ADAPTIVE APPROACH; COVERAGE; DRUG APPROVALS; ETHICAL STANDARDS; EVIDENCE COLLECTION; HEALTH TECHNOLOGY; HEALTH TECHNOLOGY ASSESSMENTS; SHARED DECISION MAKINGS;

HEALTH;

DRUG;

BIOMEDICAL TECHNOLOGY ASSESSMENT; HEALTH CARE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LICENSING; MEDICAL DECISION MAKING; MEDICAL DEVICE; MEDICAL SOCIETY; REVIEW; STANDARD; COMMERCIAL PHENOMENA; DECISION MAKING; DEVICE APPROVAL; DRUG CONTROL; HEALTH CARE DELIVERY; MANAGEMENT; MARKETING; MASS COMMUNICATION; METHODOLOGY; ORGANIZATION; PATENT; UNITED STATES;

COMMERCE; DECISION MAKING; DECISION MAKING, ORGANIZATIONAL; DEVICE APPROVAL; DIFFUSION OF INNOVATION; DRUG AND NARCOTIC CONTROL; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTELLECTUAL PROPERTY; MARKETING; POLICY MAKING; RESEARCH DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 84914710771     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462314000191     Document Type: Review

References (36)

1. Baird L, Teagarden R, Unger T, Hirsch G. New medicines eight years faster to patients: Blazing a new trail in drug development with adaptive licensing. 2013. http://goo.gl/RL1dfZ (accessed March 31, 2014
2. Baird LG, Trusheim MR, Eichler H-G, Berndt ER, Hirsch G. Comparison of stakeholder metrics for traditional and adaptive development and licensing approaches to drug development. Ther Innov Regul Sci. 2013;47:474-483
3. Boon WPC, Moors EHM,Meijer A, Schellekens H. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther. 2010 Dec;88:848-853
4. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96:179-190
5. ChangM, ChowS-C, Pong A. Adaptive design in clinical research: Issues, opportunities, and recommendations. J Biopharm Stat. 2006;16:299-309; discussion 311-312
6. Department of Health and Human Services. Speeding access to important newtherapies -fast track, breakthrough therapy, accelerated approval and priority review. http://www.fda.gov/forconsumers/byaudience/forpatient advocates/speedingaccesstoimportantnewtherapies/ucm128291.htm (accessed March 31, 2014
7. Dreyer NA, Tunis SR, Berger M, et al. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;29:1818-1825
8. Eichler H-G, Oye K, Baird LG, et al. Adaptive licensing: Taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91:426-437
9. Eijkenaar F, Emmert M, Scheppach M, Schöffski O. Effects of pay for performance in health care: A systematic review of systematic reviews. Health Policy. 2013;110:115-130
10. EMA. European Medicines Agency launches adaptive licensing pilot project. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news- andevents/news/2014/03/news-detail-002046.jsp&mid=WC0b01ac058004d5c1 (accessed March 31, 2014
11. Faulkner E,Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine-payer andmanufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR Personalized Medicine Special Interest Group. Value Health. 2012;15:1162-1171
12. Gerber A, Stock S, Dintsios CM. Reflections on the changing face of German pharmaceutical policy: How far is Germany from value-based pricing?. Pharmacoeconomics. 2011;29:549-553
13. Green Park Collaborative -Alzheimer's disease pilot. http://www. greenparkcollaborative.org/alzheimers-disease-pilot/(accessed May 9, 2014
14. Henshall C,Mardhani-Bayne L, Frønsdal KB, KlempM. Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011;27:253-260
15. Henshall C, Schuller T, HTAi Policy Forum. Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care. 2013;29:353-359
16. Henshall C, Schuller T, Mardhani-Bayne L. Using health technology assessment to support optimal use of technologies in current practice: The challenge of disinvestment. Int J Technol Assess Health Care. 2012;28:203-210
17. HTAi. About the HTAi Policy Forum. http://www.htai.org/index.php?id=643 (accessed March 31, 2014
18. HTAi. What is HTAi?. http://www.htai.org/index.php?id=420 (accessed March 31, 2014
19. Husereau D, Goeree R, Tsoi B, Masucci L, Campbell K. WHO Pan American Health Organization/Organizacion Panamericana de la Salud (PAHO/OPS): Synthesis of payer (HTA bodies) /regulator interactions for drugs and medical devices. 2013. http://dl.dropboxusercontent.com/u/27573264/DRAFT-18-Sep-Husereau-v2-Clean.pdf (accessed March 31, 2014
20. Hutton J, Trueman P, Facey K. Harmonization of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care. 2008;24:511-517
21. Innovative Medicines Initiative 2. The right prevention and treatment for the right patient at the right time. http://www.eibir.org/wp-liveeibir12-km21s/wp-content/uploads/2013/07/IMI2-Strategic- Research-Agenda-v-8-July-2013.pdf (accessed March 31, 2014
22. Kanavos P, Reinhardt U. Reference pricing for drugs: Is it compatible with U.S. health care?. Health Aff (Millwood). 2003;22:16-30
23. Klemp M, Frønsdal KB, Facey K, HTAi Policy Forum. What principles should govern the use of managed entry agreements?. Int J Technol Assess Health Care. 2011;27:77-83
24. Kreis J, Schmidt H. Public engagement in health technology assessment and coverage decisions: A study of experiences in France, Germany, and the United Kingdom. J Health Polit Policy Law. 2013;38:89-122
25. Mello MM, Goodman SN, Faden RR. Ethical considerations in studying drug safety-The Institute of Medicine report. N Engl J Med. 2012;367:959-964
26. Miller P. Role of pharmacoeconomic analysis in r&d decision making -When, where, how?. Pharmacoeconomics. 2005;23:1-12
27. Musch G. Early access and market authorization. Brussels; 2013. http://thepharmaceuticalconference.com/-docs/Greet%20Musch%20-%20Early%20access%20and%20market%20authorization.pdf (accessed December 11, 2013
28. Norman G. Commentary: Breaking the mold of normative clinical decision making: Is it adaptive, suboptimal, or somewhere in between?. Acad Med J Assoc Am Med Coll. 2010;85:393-394
29. Rabinovich M,Wood F, Shemer J. Impact of newmedical technologies on health expenditures in Israel 2000-07. Int J Technol Assess Health Care. 2007;23:443-448
30. Rawlins M. De testimonio: On the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372:2152-2161
31. Registri Farmaci sottoposti a monitoraggio [Internet]. Registri Farmaci sottoposti a monitoraggio AIFA Agenzia Italiana del Farmaco. 2014. http://www.agenziafarmaco.gov.it/it/content/registrifarmaci-sottoposti-monitoraggio (accessed March 31, 2014
32. Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, et al. An overview of international literature from cystic fibrosis registries. Part 4: Update 2011. J Cyst Fibros. 2012;11:480-493
33. Tsoi B, Masucci L, Campbell K, et al. Harmonization of reimbursement and regulatory approval processes: A systematic review of international experiences. Expert Rev PharmacoeconOutcomes Res. 2013;13:497-511
34. U.S. FDA. FDA's Sentinel Initiative -Deliverables from completed contracts. http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149343. htm (accessed March 31, 2014
35. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme?Aframework for coverage decisions. Value Health. 2012;15:570-579
36. Woodcock J. Evidence vs. access: Can twenty-first-century drug regulation refine the tradeoffs?. Clin Pharmacol Ther. 2012;91:378-380